Armune BioScience, Inc. Announces the Appointment of Sharat Singh, PhD as Research and Development Advisor

Share Article

Dr. Singh, a diagnostic industry veteran, will support the launch and ongoing research initiatives of the company’s lead product, Apifiny.

Armune BioScience has announced the appointment of Dr. Sharat Singh to the position of Research and Development Advisor. Dr. Singh, a diagnostic industry veteran, will support the launch and ongoing research initiatives of the company’s lead product, Apifiny™ - the only tumor specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer.

Dr. Singh has a significant amount of experience in research and commercialization of innovative diagnostic technologies. As the Chief Scientific Officer of Prometheus Labs, Dr. Singh led the development and commercialization of numerous diagnostic products and technical platforms which led to the acquisition of Prometheus Labs by Nestle Health Science in 2013.

“I have been involved with Armune since the early stages of the business and see great potential in the proprietary autoantibody technology. In my capacity as research and development advisor, I look forward to supporting the exciting launch of Apifiny and the expansion of the company’s product line,” said Dr. Singh.

“Sharat’s breadth of experience in research and commercialization of diagnostic technologies is a huge asset to our business as we prepare for significant growth,” said Armune President and CEO David A. Esposito. “We are seeing significant near term interest in Apifiny and Sharat’s experience will help us deliver on these opportunities. In addition, as we expand our research and development efforts, Sharat will add significant value to the growth of our product line.”

Armune BioScience, Inc. develops and commercializes autoantibody technology licensed from the University of Michigan that was developed under the direction of Arul Chinnaiyan, MD, PhD. In the coming weeks, Armune will be launching Apifiny in the United States from its laboratory in Ann Arbor, MI. Clinicians and patients interested in gaining access to Apifiny should call 844-427-6863 or request information from the company’s website at http://www.armune.com

Armune continues to raise funds through its current Series A round of investment to support the growth of the business. Interested investors should contact Eli Thomssen, Chief Business Officer, at elthomssen[at]armune.com or by telephone, 269-491-6431.

About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The Company was founded by the Apjohn Group, LLC (http://www.apjohngroup.com), a business accelerator founded by experienced health care executives that brings together valuable resources of management talent and angel/seed financing, and a group of experienced life science professionals. Armune was incorporated as a Delaware Corporation with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sue Crookston
Visit website